Distinguished in Membranous Nephropathy

Michelle A. Hladunewich

Toronto, ON, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Membranous Nephropathy
Toronto, ON, CA 
OverviewLocationsClinical Research

Overview

Michelle Hladunewich practices in Toronto, Canada. Ms. Hladunewich is rated as a Distinguished expert by MediFind in the treatment of Membranous Nephropathy. Her top areas of expertise are Focal Segmental Glomerulosclerosis, Glomerulonephritis, Membranous Nephropathy, Minimal Change Disease, and Kidney Transplant.

Her clinical research consists of co-authoring 165 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 20 articles and participated in 1 clinical trial in the study of Membranous Nephropathy.

Gender
Female

Locations

Toronto, ON, Canada
Other Locations
Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI)
Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI)
Enrollment Status: Recruiting
Publish Date: September 26, 2025
Intervention Type: Drug
Study Drug: Belimumab
Study Phase: Phase 2
A Multi-Centre 12 Month Parallel-Group Randomized Control Trial of BNT162b2 Versus mRNA( Messenger Ribonucleic Acid) -1273 COVID-19 Vaccine Boosters in Chronic Kidney Disease and Dialysis Patients With Poor Humoral Response Following COVID-19 ( Corona Virus Disease of 2019)Vaccination
A Multi-Centre 12 Month Parallel-Group Randomized Control Trial of BNT162b2 Versus mRNA( Messenger Ribonucleic Acid) -1273 COVID-19 Vaccine Boosters in Chronic Kidney Disease and Dialysis Patients With Poor Humoral Response Following COVID-19 ( Corona Virus Disease of 2019)Vaccination
Enrollment Status: Terminated
Publish Date: February 19, 2025
Intervention Type: Biological
Study Drugs: Pfizer-BioNTech COVID-19 Vaccine, MODERNA SARS-CoV-2 Vaccine
Study Phase: Phase 2/Phase 3
Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study Low Dose Study
Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study Low Dose Study
Enrollment Status: Completed
Publish Date: September 23, 2021
Intervention Type: Drug
Study Phase: Not Applicable
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS): Integrating an Assessment of the Relevance of suPAR and Activation of Podocyte β3 Integrin
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS): Integrating an Assessment of the Relevance of suPAR and Activation of Podocyte β3 Integrin
Enrollment Status: Completed
Publish Date: February 10, 2020
Intervention Type: Biological
Study Phase: Phase 2
Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: The TRANSLATE Study
Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: The TRANSLATE Study
Enrollment Status: Completed
Publish Date: January 16, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 4 Less Clinical Trials

165 Total Publications

Steroid-sparing drugs in children and young adults with nephrotic syndrome: a target trial emulation.
Steroid-sparing drugs in children and young adults with nephrotic syndrome: a target trial emulation.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: October 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hladunewich's expertise for a condition
ConditionClose
    View All 20 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile